Literature DB >> 9755233

Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors.

K P De Jong1, R Stellema, A Karrenbeld, J Koudstaal, A S Gouw, W J Sluiter, P M Peeters, M J Slooff, E G De Vries.   

Abstract

To determine whether the expression of transforming growth factor alpha (TGF-alpha), its receptor (epidermal growth factor receptor [EGFr]), p53 nuclear protein, and proliferation influences prognosis of patients with liver metastases, a study was performed in 45 liver metastases and 33 corresponding primary colorectal carcinomas in patients referred for liver surgery. The expression of TGF-alpha, EGFr, p53 nuclear protein, and proliferation rate was correlated with clinicopathological characteristics and survival after partial liver resection. In liver metastases, TGF-alpha expression was low in 42%, intermediate in 35%, and high in 23%. TGF-alpha expression was higher in liver metastases derived from lymph node-positive primary carcinomas, in synchronous and in irresectable liver metastases compared with those derived from lymph node-negative primary carcinomas, metachronous, and resectable liver metastases. Nuclear p53 expression was found in 83% of primary tumors and 71% of liver metastases. p53 expression did not correlate with the various clinicopathological characteristics. Ki67 expression was not associated with clinicopathological characteristics in primary and metastatic tumors. In the 38 patients in whom a partial liver resection was performed, median survival was 25 months in patients with a higher TGF-alpha expression in the metastasis than in the primary tumor and 60 months in patients with comparable or lower TGF-alpha expression in the metastasis than in the primary tumor (P = .036). Median survival after liver resection was 21 months in patients with p53-negative liver metastases and 58 months in patients with p53-positive metastases (P = .043). By multivariate analysis, p53 and EGFr expression on liver metastases were the best predictors of disease-free survival after partial liver resection, with relative risks of 2.38 and 3.33, respectively. In patients with colorectal liver metastases, referred for liver surgery, a higher TGF-alpha expression is associated with unfavorable tumor characteristics, whereas p53 and absence of EGFr expression is associated with a better survival after partial liver resection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9755233     DOI: 10.1002/hep.510280411

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  37 in total

1.  FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk.

Authors:  Alexandros Garouniatis; Adamantia Zizi-Sermpetzoglou; Spyros Rizos; Alkiviadis Kostakis; Nikolaos Nikiteas; Athanasios G Papavassiliou
Journal:  Int J Colorectal Dis       Date:  2012-06-26       Impact factor: 2.571

Review 2.  Liver regeneration and tumor stimulation--a review of cytokine and angiogenic factors.

Authors:  Christopher Christophi; Nadia Harun; Theodora Fifis
Journal:  J Gastrointest Surg       Date:  2008-01-08       Impact factor: 3.452

3.  Prognostic value of Ki-67 expression in conversion therapy for colorectal liver-limited metastases.

Authors:  Hiromitsu Hayashi; Toru Beppu; Yasuo Sakamoto; Yuji Miyamoto; Naomi Yokoyama; Takaaki Higashi; Hidetoshi Nitta; Daisuke Hashimoto; Akira Chikamoto; Hideo Baba
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

Review 4.  Tissue-based biomarkers predicting outcomes in metastatic colorectal cancer: a review.

Authors:  L Ung; A K-Y Lam; D L Morris; T C Chua
Journal:  Clin Transl Oncol       Date:  2014-01-24       Impact factor: 3.405

5.  Association between age and synchronous liver metastasis in female colorectal cancer patients.

Authors:  Lin Wang; Lei Wang; Wenbin Yu; Guangyong Zhang; Lifeng Zhang; Guihong Tian; Sanyuan Hu
Journal:  J Cancer Res Clin Oncol       Date:  2010-12-01       Impact factor: 4.553

6.  A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.

Authors:  Chul Kim; Jae-Lyun Lee; Min-Hee Ryu; Heung Moon Chang; Tae Won Kim; Ho Young Lim; Hye Jin Kang; Young Suk Park; Baek-Yeol Ryoo; Yoon-Koo Kang
Journal:  Invest New Drugs       Date:  2009-12-09       Impact factor: 3.850

7.  Study on the mechanism of epidermal growth factor-induced proliferation of hepatoma cells.

Authors:  Bin-Wen Wu; Yuan Wu; Jia-Long Wang; Ju-Sheng Lin; Shu-Yu Yuan; Ai Li; Wu-Ren Cui
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

8.  Modification of the primary tumor microenvironment by transforming growth factor alpha-epidermal growth factor receptor signaling promotes metastasis in an orthotopic colon cancer model.

Authors:  Takamitsu Sasaki; Toru Nakamura; Robert B Rebhun; Hua Cheng; Katherine Stemke Hale; Rachel Z Tsan; Isaiah J Fidler; Robert R Langley
Journal:  Am J Pathol       Date:  2008-07       Impact factor: 4.307

9.  Management of colorectal cancer patients after resection of liver metastases: can we offer a tailored treatment?

Authors:  Miriam López-Gómez; Paloma Cejas; María Merino; David Fernández-Luengas; Enrique Casado; Jaime Feliu
Journal:  Clin Transl Oncol       Date:  2012-08-22       Impact factor: 3.405

10.  Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors.

Authors:  Toshio Kuwai; Toru Nakamura; Takamitsu Sasaki; Sun-Jin Kim; Dominic Fan; Gabriel J Villares; Maya Zigler; Hua Wang; Menashe Bar-Eli; Robert S Kerbel; Isaiah J Fidler
Journal:  Neoplasia       Date:  2008-05       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.